19 vasario 2025
The Power of Partnership. Switzerland and China set an Example.
In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association...
13 vasario 2025
Growing Up with HD: Insights & Support Strategies with Siri Hagen Kjølaas
At last year’s EHDN & Enroll-HD Conference in Strasbourg, we had the privilege of interviewing Siri Hagen Kjølaas, Ph.D., to discuss her groundbreaking research...
06 vasario 2025
"SOM Biotech" paskelbė 2b fazės tyrimo rezultatus
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients...
30 sausio 2025
2025 m. retųjų ligų dienos kampanija
The International Huntington Association, in collaboration with the European Huntington Association, is organizing a campaign for Rare Disease Day 2025, on the 28th...
13 sausio 2025
RDI pradeda jaunimo lyderystės programą
Rare Diseases International (RDI), announced the launch of the RDI Youth Leadership Programme, an initiative designed to engage and empower young people within the...
16 gruodžio 2024 m.
Dvylikametis išleido knygą vaikams apie Huntingtono ligą
Toronto student writes book so others will treat her grandpa kindly December 11, 2024 — Toronto, Ontario, Canada Most people have never heard of Huntington’s disease....
11 gruodžio 2024 m.
"UniQure" praneša apie suderinimą su FDA dėl pagrindinių pagreitinto AMT-130 patvirtinimo kelio elementų
Vakar "uniQure" išplatino pranešimą spaudai, kuriame paskelbė, kad su JAV Maisto ir vaistų administracija (FDA) suderino pagrindinius pagreitinto patvirtinimo kelio elementus...
09 gruodžio 2024
"The Present", dokumentinis filmas su Dimitri Poffé, jau pasiekiamas per "Youtube
Dimitri Poffé yra jau žinomas HD bendruomenės narys. Po teigiamo Hantingtono ligos testo Dimitri leidosi į kelionę dviračiu per Pietų Ameriką...
09 gruodžio 2024
"PTC Therapeutics" sudaro pasaulinę licencijos ir bendradarbiavimo sutartį su "Novartis" dėl PTC518 Huntingtono ligos programos
December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory...
09 gruodžio 2024
"Sage Therapeutics" nutraukia dalzanemdoro, skirto HD gydymui, plėtrą
The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data,...